Zenith Epigenetics and Cencora have signed an agreement to expedite the commercialisation of Zenith’s ZEN-3694 programme.
This programme deploys an advanced epigenetic approach to synergistically enhance the efficacy of existing cancer drugs.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cencora will offer a range of services to plan the market launch of ZEN-3694.
Initially, the focus will be on assessing regulatory and market access to provide insights into potential opportunities and obstacles around its introduction.
These insights will help customise the development of ZEN-3694 and create patient access and adherence programmes for the entire healthcare system.
Zenith chairman, founder and CEO Donald McCaffrey stated: “For a product with the immense capabilities ZEN-3694 has, we knew we needed a partner with immeasurable experience across healthcare, unmatched distribution capabilities and a global impact.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Cencora emerged as the best partner to lead the commercial and distribution strategy for ZEN-3694 with innovation, strategic thinking and careful planning around patient access and the patient experience.”
The compound is currently under clinical development for multiple oncologic indications, with a number of studies sponsored by NCI through the NCI-Zenith co-operative research and development agreement (CRADA) and other CRADAs involving NCI and its partners.
Partners and collaborators include Astellas, BMS, Eli Lilly, GSK, Merck, Pfizer and Syndax.
The programme is also supported by several further collaborators and partners, including Dana Farber – Harvard, MD Anderson, Memorial Sloan Kettering, the National Cancer Institute, the National Institute of Health, UCSF and Yale.
Cencora International Commercialisation senior vice-president Sandra Anderson stated: “We are thrilled to support Zenith’s pre-commercial launch preparations and will provide the solutions they need to help them accelerate time-to-market and maximise commercial success.”
